The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
https://doi.org/10.70776/KVJG2814
Leslie Myers PharmD, IgCP, CSI Pharmacy | Elizabeth Neal RN, IgCN, CSI Pharmacy | Edward O’Bryan MD, MBA, CPE, CSI Pharmacy | Michele Way PharmD, IgCP, BCSCP, CSI Pharmacy | Taylor Cathcart RN, CSI Pharmacy | Elizabeth Duruz R.Ph., CSP, IgCP, CSI Pharmacy | James Sheets PharmD, IgCP, CSI Pharmacy | Timothy P. Walton MHS, CCRP, CSI Pharmacy
Home infusion therapy is an established alternative site of care, from a hospital or outpatient infusion center, for patients requiring administration of infusion medications through a needle or venous access device.
The National Home Infusion Association (NHIA) is proud to announce that Melissa Leone, RN, BSN, FNHIA has been selected as the recipient of the 2026 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) is proud to announce its 2026-2027 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization.
https://doi.org/10.70776/DGES5928
Natalie Garcia PharmD, Option Care Health | Andrew Chinn PharmD, BCSCP, Option Care Health | Cara Bivona, PharmD Option Care Health | Maria Giannakos PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP, Option Care Health | Michelle Sahlani PharmD, Option Care Health | David Shepherd PharmD, CNSC, BCSCP, Option Care Health
Infliximab and its biosimilars are used to treat several chronic inflammatory conditions. While standard dosing is effective, patients can experience loss of response and require dose escalation, shortening dose intervals or higher doses.
The National Home Infusion Association (NHIA) is releasing Infusion Industry Trends, the latest assessment of the home and alternate site infusion industry’s market position. Based on claims data from a 3-year timeframe, this focused analysis shows how the industry is evolving across therapy categories and payor environments.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2026. The authors of the following 4 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
The National Home Infusion Association (NHIA) has received clarification from CMS regarding enrollment options for home infusion pharmacies under the current nationwide DMEPOS enrollment moratorium.
The 2026 government funding for Health and Human Services that passed the House of Representatives today includes a change to the qualifying criteria for drugs under Medicare’s home infusion benefit that may expand access to certain health care provider-administered drugs if an infusion pump is required for administration. Passage of H.R. 4993, the Joe Fiandra Access to Home Infusion Act, reflects Congress’ recognition of the strong patient interest—including among individuals with rare diseases—in home infusion access.
National Home Infusion Association (NHIA) President and CEO Connie Sullivan testified today before the House Energy and Commerce Committee Subcommittee on Health in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172). The hearing marked a major milestone for the legislation, with Members from both parties emphasizing the need to strengthen Medicare and remove barriers that keep seniors from receiving clinically appropriate infusion care at home.
NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for the NHIA member organization. Seats are open to provider members and are assigned at the organization level. Two seats are currently available for hospital providers (a provider that is wholly owned and operated as part of an acute care system).
The National Home Infusion Association (NHIA) and Inovalon are pleased to announce the addition of Inovalon to NHIA’s Future of Infusion Advisory Council (FIAC).
https://doi.org/10.70776/QHAL9260
Kimberly Duff, RN, BSN Clinical Sciences, R&D Takeda Development Center Americas, Inc. | Stefan Holzner, PhD* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Madeleine Gibson, MSIE* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Seth Jones, BSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Scott Ariagno, MSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. *Affiliation at the time of the study
Facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is packaged as a dual-vial unit of immunoglobulin G 10% (labelled ‘IG’) and recombinant human hyaluronidase (rHuPH20; labelled ‘HY’) for use as a prescribed immunoglobulin treatment for patients with primary or secondary immunodeficiency and chronic inflammatory demyelinating polyradiculoneuropathy.
https://doi.org/10.70776/ZJVE7679
Devin Wall, RN KORU Medical Systems | Elizabeth M. Younger, CRNP, PhD Johns Hopkins University School of Medicine | Kelvin Shaw, MD Allergy and ENT Associates | Chris Pratt, PharmD CVS Suzanne Strasters, FNP-C GC Biopharma | Sam Mihelich, PharmD NuFactor Specialty Pharmacy | Will Holland, PharmD Realo Specialty Care | Sarah Taylor, RN Realo Specialty Care | Kolleen Casey, BSN KH Nursing Services | Nicole Graves, RN RxCrossroads
Subcutaneous immune globulin (SCIG) therapy is a flexible, patient-centered alternative to intravenous immune globulin (IVIG). While increasingly popular in home and specialty infusion care, managing the ancillary supplies for SCIG therapy remains complex. Current literature offers general guidance on SCIG administration but lacks detailed consensus on best practices for supply management, infusion site selection, and training requirements.
https://doi.org/10.70776/WMSV6374
Kascha Brown PharmD, MS Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP Option Care Health | Annemarie Hocking PharmD Option Care Health
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by vaso-occlusive crises (VOCs), leading to significant morbidity and health care utilization. Crizanlizumab, a P-selectin inhibitor, was approved in 2019 to reduce the frequency of VOCs. Limited data are available on the utilization and tolerability of crizanlizumab administered in home and alternate infusion site (AIS) settings.
The National Home Infusion Association (NHIA) is pleased to announce the 2026 Fellow Program (FNHIA) cohort, made up of highly accomplished home and alternate site infusion professionals.
The National Home Infusion Foundation (NHIF) is proud to announce Barbara Petroff, MS, RPh, BCSCP, CAC, CSPP, IgCP, FNHIA, FASHP as the recipient of the 2026 Women in Leadership Award.
https://doi.org/10.70776/TJLU1217
Jennifer Zhao PharmD, Johns Hopkins Care at Home | Tricia Schneider PharmD, MBA, Johns Hopkins Care at Home | Krista Decker RPh, MSQA, Johns Hopkins Care at Home
Drug utilization review (DUR) systems are important for ensuring medication safety by identifying medication-related issues, such as Drug-Drug interactions and therapy duplications. While DUR
alerts support clinical decision-making, excessive or clinically irrelevant alerts can lead to alert fatigue. This can potentially cause pharmacists to overlook crucial warnings and jeopardize patient safety.
https://doi.org/10.70776/KVJG2814
Leslie Myers PharmD, IgCP, CSI Pharmacy | Elizabeth Neal RN, IgCN, CSI Pharmacy | Edward O’Bryan MD, MBA, CPE, CSI Pharmacy | Michele Way PharmD, IgCP, BCSCP, CSI Pharmacy | Taylor Cathcart RN, CSI Pharmacy | Elizabeth Duruz R.Ph., CSP, IgCP, CSI Pharmacy | James Sheets PharmD, IgCP, CSI Pharmacy | Timothy P. Walton MHS, CCRP, CSI Pharmacy
Home infusion therapy is an established alternative site of care, from a hospital or outpatient infusion center, for patients requiring administration of infusion medications through a needle or venous access device.
The National Home Infusion Association (NHIA) is proud to announce that Melissa Leone, RN, BSN, FNHIA has been selected as the recipient of the 2026 Gene Graves Lifetime Achievement Award.
The National Home Infusion Association (NHIA) is proud to announce its 2026-2027 Board of Directors. Board members serve 3-year terms as representatives for their NHIA member organization.
https://doi.org/10.70776/DGES5928
Natalie Garcia PharmD, Option Care Health | Andrew Chinn PharmD, BCSCP, Option Care Health | Cara Bivona, PharmD Option Care Health | Maria Giannakos PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP, Option Care Health | Michelle Sahlani PharmD, Option Care Health | David Shepherd PharmD, CNSC, BCSCP, Option Care Health
Infliximab and its biosimilars are used to treat several chronic inflammatory conditions. While standard dosing is effective, patients can experience loss of response and require dose escalation, shortening dose intervals or higher doses.
The National Home Infusion Association (NHIA) is releasing Infusion Industry Trends, the latest assessment of the home and alternate site infusion industry’s market position. Based on claims data from a 3-year timeframe, this focused analysis shows how the industry is evolving across therapy categories and payor environments.
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2026. The authors of the following 4 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.
The National Home Infusion Association (NHIA) has received clarification from CMS regarding enrollment options for home infusion pharmacies under the current nationwide DMEPOS enrollment moratorium.
The 2026 government funding for Health and Human Services that passed the House of Representatives today includes a change to the qualifying criteria for drugs under Medicare’s home infusion benefit that may expand access to certain health care provider-administered drugs if an infusion pump is required for administration. Passage of H.R. 4993, the Joe Fiandra Access to Home Infusion Act, reflects Congress’ recognition of the strong patient interest—including among individuals with rare diseases—in home infusion access.
National Home Infusion Association (NHIA) President and CEO Connie Sullivan testified today before the House Energy and Commerce Committee Subcommittee on Health in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172). The hearing marked a major milestone for the legislation, with Members from both parties emphasizing the need to strengthen Medicare and remove barriers that keep seniors from receiving clinically appropriate infusion care at home.
NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for the NHIA member organization. Seats are open to provider members and are assigned at the organization level. Two seats are currently available for hospital providers (a provider that is wholly owned and operated as part of an acute care system).
The National Home Infusion Association (NHIA) and Inovalon are pleased to announce the addition of Inovalon to NHIA’s Future of Infusion Advisory Council (FIAC).
https://doi.org/10.70776/QHAL9260
Kimberly Duff, RN, BSN Clinical Sciences, R&D Takeda Development Center Americas, Inc. | Stefan Holzner, PhD* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Madeleine Gibson, MSIE* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Seth Jones, BSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Scott Ariagno, MSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. *Affiliation at the time of the study
Facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is packaged as a dual-vial unit of immunoglobulin G 10% (labelled ‘IG’) and recombinant human hyaluronidase (rHuPH20; labelled ‘HY’) for use as a prescribed immunoglobulin treatment for patients with primary or secondary immunodeficiency and chronic inflammatory demyelinating polyradiculoneuropathy.
https://doi.org/10.70776/ZJVE7679
Devin Wall, RN KORU Medical Systems | Elizabeth M. Younger, CRNP, PhD Johns Hopkins University School of Medicine | Kelvin Shaw, MD Allergy and ENT Associates | Chris Pratt, PharmD CVS Suzanne Strasters, FNP-C GC Biopharma | Sam Mihelich, PharmD NuFactor Specialty Pharmacy | Will Holland, PharmD Realo Specialty Care | Sarah Taylor, RN Realo Specialty Care | Kolleen Casey, BSN KH Nursing Services | Nicole Graves, RN RxCrossroads
Subcutaneous immune globulin (SCIG) therapy is a flexible, patient-centered alternative to intravenous immune globulin (IVIG). While increasingly popular in home and specialty infusion care, managing the ancillary supplies for SCIG therapy remains complex. Current literature offers general guidance on SCIG administration but lacks detailed consensus on best practices for supply management, infusion site selection, and training requirements.
https://doi.org/10.70776/WMSV6374
Kascha Brown PharmD, MS Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP Option Care Health | Annemarie Hocking PharmD Option Care Health
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by vaso-occlusive crises (VOCs), leading to significant morbidity and health care utilization. Crizanlizumab, a P-selectin inhibitor, was approved in 2019 to reduce the frequency of VOCs. Limited data are available on the utilization and tolerability of crizanlizumab administered in home and alternate infusion site (AIS) settings.
